New Organ Damage Rare in Well-Controlled Lupus Pregnancies
New irreversible organ damage occurred in just over four percent of pregnancies among women with predominantly well-controlled systemic lupus erythematosus, according to a longitudinal study published on October 22 in Lupus Science & Medicine and reported by medscape.com. Researchers evaluated records collected prospectively from pregnancy clinics at the University of Pisa and the University of Padua in Italy, tracking 165 pregnancies across 126 women between 2000 and 2024 to determine whether gestation increases short-term organ damage in patients with the autoimmune condition.
-
Key Clinical Takeaways:
- New organ damage accrued in only 4.2% of the studied pregnancies, with each affected case involving a single-point increase on the Systemic Lupus International Collaborating Clinics Damage Index.
- Preexisting organ damage associated with further progression, raising the odds of additional damage accrual by nearly sevenfold.
- Disease flares and obstetric complications showed no clear association with damage progression in the full cohort, though wide confidence intervals precluded definitive conclusions.
Organ Damage Progression Rates in SLE Pregnancies
The study, led by Dina Zucchi of the Rheumatology Unit at the Azienda Ospedaliero-Universitaria Pisana, assessed damage accrual using the Systemic Lupus International Collaborating Clinics Damage Index (SDI) during two distinct 12-month windows: the year before conception and the year following it. Among the 165 pregnancies analyzed, new damage events emerged in seven instances, representing 4.2% of the total cohort. Every single event was restricted to a 1-point increase on the SDI scale. The recorded events comprised one case each of bilateral cataract, osteoporotic fracture, malignancy, deep vein thrombosis, scarring alopecia, renal impairment, and diabetes.
Mean SDI scores shifted marginally from 0.18 at one year before conception to 0.22 one year after conception, while the median change remained at zero. During the prepregnancy reference period, damage had accrued in two of the 165 pregnancies, equating to 1.2%. As reported by medscape.com, the authors did not formally test the statistical difference between the two periods. Participants entered the study with a mean age of 32.9 years and a median disease duration of 10 years. At the final prepregnancy visit, the mean Systemic Lupus Erythematosus Disease Activity Index 2000 score sat at 2.3, with 6.9% of patients exhibiting active disease.
Baseline Damage as a Predictor of Further Progression
Patients who experienced damage progression entered pregnancy with higher baseline SDI scores than those who did not, averaging 0.71 compared to 0.17. Preexisting damage demonstrated a clear association with further progression, yielding an odds ratio of 6.77 with a 95% confidence interval ranging from 1.43 to 32.05. Estimated progression risks climbed across baseline categories, registering at 2.2% for patients with a score of zero, 13.0% for a score of one, and 33.3% for a score of two. The researchers noted that these particular estimates derived from very small subgroups and carried notable imprecision.
In a sensitivity analysis restricted exclusively to each woman’s first recorded pregnancy, damage accrual appeared in six out of 126 women, confirming the persistence of the association between preexisting damage and progression. This sensitivity analysis also identified higher prepregnancy disease activity as an associated factor, though that particular link remained inconclusive across the full cohort.
Flares and Treatment Exposures Show No Clear Association with Damage
Disease flares occurred in 20.6% of the pregnancies evaluated in the primary cohort, with the vast majority—79.4%—classified as mild to moderate in severity. However, neither flares, obstetric complications, nor treatment exposures established a clear association with subsequent damage progression. Because the absolute number of damage events was low and confidence intervals remained wide, the research team cautioned that firm conclusions regarding these secondary clinical factors cannot be drawn from the data.
The investigators pointed out several limitations inherent in their analysis. The small number of damage events restricted statistical power and prevented reliable multivariable modeling. Data regarding cumulative glucocorticoid exposure were limited due to gaps in detailed longitudinal dosing records, and the investigation lacked a matched control group of nonpregnant women with systemic lupus erythematosus. The study received no specific funding, and the authors reported no conflicts of interest.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.